# US 8,003,323 B2 · Reduction in bacterial colonization by administering bacteriophage compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,003,323 B2
- Document ID: US8003323B2
- Status: Granted
- Kind: B2
- Application number: 12/264,582
- Filed: 2008-11-04
- Published: 2009-02-26
- Granted: 2011-08-23
- Earliest claimed: 2000-01-11
- Assignees: Intralytix, Inc.
- Inventors: J. Glenn Morris; Alexander Sulakvelidze; Zemphira Alavidze; Gary R. Pasternack; Torrey C. Brown
- Web page: https://patentgrep.com/patent/US8003323B2

## CPC

- C08L 77/12: Polyester-amides
- A01N 63/40: Viruses, e.g. bacteriophages
- A23B 2/7295: {Antibiotics}
- A23B 2/783: Microorganisms; Enzymes
- A23B 4/22: Microorganisms; Enzymes; {Antibiotics}
- A23B 7/155: Microorganisms; Enzymes {; Antibiotics}
- A23G 9/30: Cleaning; Keeping clean; Sterilisation
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 38/164: {from bacteria}
- A61L 2/00: Disinfection or sterilisation of materials or objects, in general; Accessories therefor
- A61L 2/18: Liquid substances
- A61L 2/22: Phase substances, e.g. smokes or aerosols
- A61L 15/225: {Mixtures of macromolecular compounds}
- A61L 15/26: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof {(A61L15/225 takes precedence)}
- A61L 15/38: containing enzymes
- A61L 15/44: Medicaments
- A61L 26/0019: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds}
- A61L 26/0052: {Mixtures of macromolecular compounds}
- A61L 26/0066: {Medicaments; Biocides}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- C08G 69/44: Polyester-amides
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61L 2103/05: Living organisms or biological materials
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/00051: Methods of production or purification of viral material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A23B: PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23G: COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

## Claims

### Claim 1

A method for reducing risk of bacterial infection in an animal colonized with bacteria comprising treating an animal with a composition containing bacteriophage of one or more strains which produce lytic infections in said bacteria, said animal having been colonized by said bacteria for at least 24 hours, but not infected with said bacteria, wherein said treatment of the animal reduces the level of colonization with bacteria susceptible to the bacteriophage by at least one log, and wherein said composition is administered intravesicularly, topically, orally, rectally, ocularly, otically, nasally, or via inhalation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the bacteria are selected from the group consisting of VRE, pneumococcal species, methicillin-resistant Staphylococcus species, MDRSA, multi-drug resistant Pseudomonas species, Neisseria sp., Hemophilus sp., Proteus sp., Klebsiella sp. Salmonella, Campylobacter, Listeria, and Esherichia coli.

### Claim 3 (depends on 2)

The method of claim 2, wherein the bacteria are Salmonella.

### Claim 4 (depends on 2)

The method of claim 2, wherein the bacteria are Esherichia coli.

### Claim 5 (depends on 2)

The method of claim 2, wherein the bacteria are Esherichia coli O157:H7.

### Claim 6 (depends on 2)

The method of claim 2, wherein the bacteria are Campylobacter.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition contains a plurality of bacteriophage strains.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition contains bacteriophage strains which produce lytic infections in bacteria of a plurality of bacterial strains.

### Claim 9 (depends on 7)

The method of claim 7, wherein the composition contains bacteriophage strains which produce lytic infections in bacteria of a plurality of bacterial species.

### Claim 10 (depends on 1)

The method of claim 1, wherein said animal is a farm animal.

### Claim 11 (depends on 10)

The method of claim 10, wherein said farm animal is poultry or livestock.

### Claim 12 (depends on 11)

The method of claim 11, wherein said poultry is a chicken.

### Claim 13 (depends on 10)

The method of claim 10, wherein said farm animal is a cow.

### Claim 14 (depends on 10)

The method of claim 10, where said farm animal is veal calves.

### Claim 15 (depends on 1)

The method of claim 1, wherein the composition is selected from the group consisting of an oral tablet, capsule or liquid, a nasal aerosol, a throat wash, a mouth wash or gargle, a toothpaste, rinses, creams, aerosols and a topical ointment.

### Claim 16 (depends on 1)

The method of claim 1, wherein said animal is a chicken and said bacteria are Salmonella.

### Claim 17 (depends on 1)

The method of claim 1, wherein said animal is a chicken and said bacteria are E. coli.

### Claim 18

A method for reducing the level of colonization by particular bacteria in a population of farm animals comprising administering to farm animals a preparation of bacteriophage lytic for said bacteria, said farm animals having been colonized by said bacteria for at least 24 hours, but not infected with said bacteria, whereby colonization levels in said farm animals are reduced by at least one log, and wherein the preparation is administered intravesicularly, topically, orally, rectally, ocularly, otically, nasally, or via inhalation.

### Claim 19 (depends on 18)

The method of claim 18, wherein the bacteria are selected from the group consisting of VRE, pneumococcal species, methicillin-resistant Staphylococcus species, MDRSA, multi-drug resistant Pseudomonas species, Neisseria sp., Hemophilus sp., Proteus sp., Klebsiella sp. Salmonella, Campylobacter, Listeria, and Esherichia coli.

### Claim 20 (depends on 19)

The method of claim 19, wherein the bacteria are Salmonella.

### Claim 21 (depends on 19)

The method of claim 19, wherein the bacteria are Esherichia coli.

### Claim 22 (depends on 19)

The method of claim 19, wherein the bacteria are Esherichia coli O157:H7.

### Claim 23 (depends on 19)

The method of claim 19, wherein the bacteria are Campylobacter.

### Claim 24 (depends on 18)

The method of claim 18, wherein the preparation contains a plurality of bacteriophage strains.

### Claim 25 (depends on 24)

The method of claim 24, wherein the preparation contains bacteriophage strains which produce lytic infections in bacteria of a plurality of bacterial strains.

### Claim 26 (depends on 24)

The method of claim 24, wherein the preparation contains bacteriophage strains which produce lytic infections in bacteria of a plurality of bacterial species.

### Claim 27 (depends on 18)

The method of claim 18, wherein said farm animal is poultry or livestock.

### Claim 28 (depends on 27)

The method of claim 27, wherein said poultry is a chicken.

### Claim 29 (depends on 27)

The method of claim 27, wherein said farm animal is a cow.

### Claim 30 (depends on 27)

The method of claim 27, where said farm animal is veal calves.

### Claim 31 (depends on 18)

The method of claim 18, wherein the preparation is selected from the group consisting of an oral tablet, capsule or liquid, a nasal aerosol, a throat wash, a mouth wash or gargle, a toothpaste, rinses, creams, aerosols and a topical ointment.

### Claim 32 (depends on 18)

The method of claim 18, wherein said animal is a chicken and said bacteria are Salmonella.

### Claim 33 (depends on 18)

The method of claim 18, wherein said animal is a chicken and said bacteria are E. coli.

### Claim 34 (depends on 1)

The method of claim 1, wherein said composition is administered periodically or continuously.

### Claim 35 (depends on 18)

The method of claim 18, wherein said preparation is administered periodically or continuously.
